Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1016-1021., 2021.
Article
in Zh
| WPRIM
| ID: wpr-876643
Responsible library:
WPRO
ABSTRACT
Chronic hepatitis B (CHB) is a major global public health issue, and although direct-acting antiviral agents can control hepatitis B virus (HBV) replication, it is difficult to achieve the cure of CHB. Host adaptive immune response plays a key role in eliminating HBV, and it is expected to achieve the functional cure of CHB by rebuilding the patient’s adaptive immunity. Great progress has been made in therapeutic vaccines, cellular immunotherapy, immune checkpoint blockade, T cell metabolic reprogramming, and strategies of neutralizing antibody targeting adaptive immunity for the treatment of hepatitis B. This article summarizes the above-mentioned therapies for hepatitis B in recent years.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Clinical Hepatology
Year:
2021
Type:
Article